FIELD: pharmacology.
SUBSTANCE: invention relates to heterocyclic pyrimidine compounds of formula I
and to pharmaceutical compositions based thereon.
EFFECT: new compounds are obtained that modulate the mutant-selective kinase activity of epidermal growth factor receptors and which are useful in treatment of diseases associated with the epidermal growth factor kinase activity.
46 cl, 1 dwg, 6 tbl, 61 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/β-CATENIN SIGNAL INHIBITORS | 2012 |
|
RU2627693C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
| ERBB/BTK INHIBITORS | 2019 |
|
RU2764069C1 |
| 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE COMPOUNDS | 2013 |
|
RU2671976C2 |
| COMPOUNDS AND COMPOSITIONS FOR MODULATING KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2822389C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2018 |
|
RU2801302C2 |
| HISTONE DEACETYLASE INHIBITORS | 2014 |
|
RU2673819C2 |
